BRISTOL-MEYERS SQUIBB AND PFIZER
In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb’s long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in this field.
Biotherapies for Life
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies, which are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself.
Our commitment to improving the quality of life for people with serious and rare conditions is evident in everything we do. Whether we are manufacturing and marketing effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our customers’ needs.
CSL Behring is a Founding Partner of ECTH
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo can draw upon a rich legacy of innovation and a robust pipeline of promising medicines. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. Daiichi Sankyo’s European base is located in Munich and has affiliates in 12 European countries.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. Our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Our vision is to be a trusted leader in changing the practice of medicine.
AryoGen Biopharma, established in 2009 is a biopharmaceutical manufacturer. Benefiting from high ranking experts in biopharmaceutical production technologies. AryoGen Biopharma provides 4 biosimilars (rFVIIa, Rituximab, Etanercept and Trastuzumab) to the market and also some in its pipeline. AryoGen biopharma has started registration of its products in 35 countries.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Grifols is a global healthcare company with more than 75-year legacy of improving people’s health and well-being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products.
Health commitment drives our activity organized into three divisions: Bioscience, Diagnostic, and Hospital, which develop, produce and market innovative products to medical professionals in more than 100 countries worldwide.
HYPHEN BioMed is highly specialized for developing, manufacturing and distributing in-vitro diagnostic and research reagents for the exploration of thrombosis and haemostasis. Being expert in the field, the company provides innovative and value-adding solutions to hospital laboratories (e.g., DOACs, HIT, Haemophilia), research institutions and pharmaceutical industry (customized offer), worldwide through an extensive distribution network.
Kedrion Biopharma collects and fractionates blood plasma to produce plasma-derived therapies for use in treating hemophilia, immunodeficiencies and other serious illnesses.
Kedrion bridges donors and patients, and works globally to expand access to treatments. It’s the world’s 5th most important player in the field of plasma derivatives; its products include coagulation factors, immunoglobulins and albumin.
LFB is a biopharmaceutical company that develops, manufactures and markets medicines indicated in the treatment of serious and often rare diseases in some major therapeutic areas: hemostasis, immunology and intensive care. LFB is number one in France and sixth worldwide in the field of plasma-derived medicines.
Sobi is a pioneer in rare diseases. Our history of innovation in haemophilia treatments stretches over
50 years. We have the simple goal to provide people with haemophilia treatment choices that will help them live the lives they want.
Please visit: www.sobihaemophilia.com
Stago, created in 1945, is an IVD Company which develops and markets reagents and automated systems for the investigation of blood coagulation disorders. Stago is a leading player in Haemostasis. Its products are available in more than 110 countries throughout the world through a network of 14 affiliates and 95 distributors.
The Hague, International City of Peace and Justice: third largest city in the Netherlands, official seat of the Crown and Government, home to hundreds of international organisations and multinationals, and one of the world’s top three UN cities.
See for more information https://denhaag.com/en/.